Aspira Women’s Health Appoints John Ragard to Its Board of Directors

AUSTIN, Texas, July 29, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bioanalytical women’s health company focused on developing diagnostic tools for gynecological diseases, today announced the appointment of Mr. John Ragard to its Board of Directors. Mr. Ragard is a seasoned executive with extensive experience successfully managing several billion-dollar portfolios over the course of his career.

“We are pleased to welcome John to our Board of Directors,” said Jannie Herchuk, Chair of Aspira Women’s Health. “John brings a wealth of experience and a deep understanding of Wall Street, having been a successful financial executive for the past four decades. He will be an important voice on our Board of Directors as we continue to build Aspira into a world-class company that delivers a new standard of care in women’s health.”

Nicole Sandford, CEO of Aspira Women’s Health, said: “John is an excellent addition to the board. As a seasoned investment professional, John understands what Aspira needs to do to attract and retain long-term investors. He has followed the company closely for many years and as a result will quickly add valuable insights that will help us execute on our next phase of accelerated growth.”

Mr. John Ragard has spent more than 46 years as a venture capitalist, buy-side analyst and portfolio manager. Mr. Ragard is currently a Senior Investment Advisor at Wayve Capital Management after more than six years as a portfolio manager at Spouting Rock, where he co-managed a small growth stock portfolio that outperformed the benchmark over a 5-year period and since inception. Prior to Spouting Rock, Mr. Ragard was a portfolio manager at Friess Associates, where he outperformed the Russell 3000 Growth Index by more than 400 basis points annually for more than 20 years. Mr. Ragard earned a Bachelor of Science in Economics with honors from the Wharton School and is a Chartered Financial Analyst.

Mr. Ragard added: “I am delighted to be joining this group of dedicated executives. I have long believed in the promise of Aspira’s compelling portfolio and I look forward to working closely with them as we take the company to the next level.”

About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. discovers, develops, and commercializes non-invasive, artificial intelligence-enabled tests that aid in the diagnosis of gynecological conditions.

OvaWatch^® and Ova1Plus^® are offered to physicians as OvaSuite^MS. Together, they provide the only comprehensive blood test kit that helps detect ovarian cancer in the more than 1.2 million American women diagnosed with an adnexal mass each year. OvaWatch has a negative predictive value of 99% and is used to assess the risk of ovarian cancer in women whose initial clinical assessment indicates that the mass is indeterminate or benign and that surgery may be premature or unnecessary. Ova1Plus is a reflex process of two FDA-approved tests, Ova1^® and Over^®to assess the risk of ovarian cancer in women planning surgery.

Our ongoing testing program is designed to expand our ovarian cancer research portfolio and address the critical need for noninvasive diagnostics for endometriosis, a devastating disease that affects millions of women worldwide. For ovarian cancer, our OvaMDx^MS risk assessment aims to combine microRNA and protein biomarkers with patient data to further increase the sensitivity and specificity of our current tests. In endometriosis, EndoCheck^MS is the first noninvasive test designed to identify endometriosis, one of the most common forms of endometriosis. EndoMDx^MS The test aims to combine microRNA and protein biomarkers with patient data to detect any cases of endometriosis.

Forward-looking statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products under development and other statements that are predictive in nature. Actual results may differ materially from those discussed due to known and unknown risks, uncertainties and other factors. These forward-looking statements generally can be identified by the use of words such as “designed to,” “expect,” “plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,” “future,” other words of similar meaning and the use of future dates. The forward-looking statements in this press release and other factors that could cause such differences include the satisfaction of customary closing conditions related to the offering and the expected time to close the offering. These and additional risks and uncertainties are described in more detail in the Company’s filings with the SEC, including those identified as “Risk Factors” in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira does not currently know about or that Aspira currently believes to be immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira’s expectations, plans or projections regarding future events and views as of the date of this press release. Subsequent events and developments could cause the Company’s assessments to change. However, although Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. You should not rely on these forward-looking statements as representing Aspira’s judgment as of any date after the date of this press release. Accordingly, you should not place undue reliance on these forward-looking statements.

Contact for investors:
Nicole Sandford
General Director
[email protected]